BiotechTube

Tenapanor 50 MG + Tenapanor 25 mg bid + Placebo

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 41/100
41
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Irritable Bowel Syndrome With Constipation (IBS-C)

Conditions

Irritable Bowel Syndrome With Constipation (IBS-C)

Trial Timeline

Nov 15, 2022 → Jun 1, 2026

NCT ID
NCT05643534

About Tenapanor 50 MG + Tenapanor 25 mg bid + Placebo

Tenapanor 50 MG + Tenapanor 25 mg bid + Placebo is a phase 3 stage product being developed by Ardelyx for Irritable Bowel Syndrome With Constipation (IBS-C). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05643534. Target conditions include Irritable Bowel Syndrome With Constipation (IBS-C).

What happened to similar drugs?

7 of 20 similar drugs in Irritable Bowel Syndrome With Constipation (IBS-C) were approved

Approved (7) Terminated (1) Active (13)
✅Ramosetron + PlaceboAstellas PharmaApproved
✅Ramosetron + PlaceboAstellas PharmaApproved
✅duloxetineEli LillyApproved
✅Bacillus clausii + MetronidazoleSanofiApproved
✅Iberogast® and Iberogast® NBayerApproved
✅LinaclotideIronwood PharmaceuticalsApproved
✅Linaclotide + PlaceboIronwood PharmaceuticalsApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05643534Phase 3Recruiting

Competing Products

20 competing products in Irritable Bowel Syndrome With Constipation (IBS-C)

See all competitors
ProductCompanyStageHype Score
linaclotide + placeboAstellas PharmaPhase 2
35
YM060 + PlaceboAstellas PharmaPhase 3
40
Ramosetron + PlaceboAstellas PharmaApproved
43
Ramosetron + PlaceboAstellas PharmaApproved
43
YM060Astellas PharmaPhase 3
40
YM060 + placeboAstellas PharmaPhase 2
35
YM060Astellas PharmaPhase 3
40
linaclotide + PlaceboAstellas PharmaPhase 3
40
RamosetronAstellas PharmaPre-clinical
26
YM060Astellas PharmaPhase 2
35
ONO-2952 + Placebo comparatorOno PharmaceuticalPhase 2
27
ONO-2952 + ONO-2952 Matching PlaceboOno PharmaceuticalPhase 2
35
duloxetineEli LillyApproved
43
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)AbbViePhase 3
40
25mg Eluxadoline + 100mg EluxadolineAbbViePhase 3
47
Eluxadoline + PlaceboAbbViePhase 2
42
Placebo + LinaclotideAstraZenecaPhase 3
40
TegaserodNovartisPre-clinical
26
DNK333NovartisPhase 2
35
SMS995 + PlaceboNovartisPhase 1
29